Compare Deere & Company (DE) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deere & Company vs Merck & Co., Inc. — how do they compare? Deere & Company trades at $621.93 (market cap $175.95B), while Merck & Co., Inc. trades at $145.95 (market cap $351.28B). The key difference: Merck & Co., Inc. is the larger of the two by market cap, and Merck & Co., Inc. pays the higher dividend (2.39%). Which is the better fit depends on your goals — on Pluang, investors hold Deere & Company for 75 Days and Merck & Co., Inc. for 98 Days on average.
| DE | MRK | |
|---|---|---|
Market Cap | $175.95B | $351.28B |
Volume | 1,387,231 | 7,969,665 |
Sector | Industrials | Health |
52-Week High | $709.48 | $156.43 |
52-Week Low | $439.11 | $82.49 |
Typical Hold Time | 75 Days | 98 Days |
Enterprise Value | $229.85B | $398.04B |
Dividend Yield | 0.99% | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deere & Company (DE) trades at $627.66, down 4.45% on the day, reflecting near-term pressure amid a bearish technical signal. The stock has demonstrated consistent earnings beats in recent quarters, with Q2 2026 EPS of $5.10 surpassing the $4.69 estimate. However, revenue has declined from $60.2B in 2023 to $44.7B in 2025, compressing net margins. Analyst consensus remains optimistic with a $731.20 price target, supported by a 43.48% buy rating.
The outlook balances strong profitability metrics like an 18.4% ROE against cyclical headwinds in the agriculture equipment sector. Key risks include further revenue contraction and high debt levels, but institutional accumulation and a strategic focus on AI-driven farming solutions present long-term growth catalysts. The current valuation at a P/E of 36.27 demands sustained earnings expansion to justify upside.
Merck (MRK) trades at $145.6, up 1.97% today, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company is expanding its oncology pipeline through the acquisition of Terns Pharmaceuticals. Revenue growth is steady, with 2025 revenue at $65.01B and net income of $18.25B, though 2026 projections show a significant drop in net income to $3.2B. The stock is supported by a high analyst buy consensus of 68.42% and a price target of $158.78.
The outlook for MRK is mixed; strong earnings beats and strategic acquisitions provide upside potential, but high valuation ratios and a projected earnings decline in 2026 pose risks. Investors should weigh the company's robust profitability and analyst support against execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Deere & Company
Deere is the world's leading manufacturer of agricultural equipment, producing some of the most recognizable machines in the heavy machinery industry. The company is divided into four reportable segments: production and precision agriculture, small agriculture and turf, construction and forestry, and John Deere Capital. Its products are available through an extensive dealer network, which includes over 1,900 dealer locations in North America and approximately 3,700 locations globally. John Deere Capital provides retail financing for machinery to its customers, in addition to wholesale financing for dealers, which increases the likelihood of Deere product sales.
Read more on DE →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
